Myriad Genetics, Inc. (MYGN) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Myriad Genetics, Inc. (MYGN) for potential violations of federal securities laws. This follows UnitedHealth Group's decision to stop covering Myriad's GeneSight test starting January 1, 2025.
November 15, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Myriad Genetics is under investigation for potential securities law violations after UnitedHealth announced it will stop covering the GeneSight test.
The investigation by Levi & Korsinsky into Myriad Genetics for potential securities law violations is significant, especially following UnitedHealth's decision to cease coverage of GeneSight. This could negatively impact Myriad's stock due to potential legal repercussions and loss of revenue from GeneSight.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100